Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland - supplementary material

<b>Figure S1.</b> Model schematic.Curves provided in this image are hypothetical to illustrate how health state occupancy is determined. OS: overall survival; PD: progressed disease; PF: progression free; PFS: progression-free survival.<b>Figure S2.</b> Parametric survival model extrapolations for OS (avelumab + BSC). BSC: best supportive care; KM: Kaplan-Meier; OS: overall survival.<b>Figure</b><b> S3</b><b>.</b> Parametric survival model extrapolations for OS (BSC). BSC: best supportive care; KM: Kaplan-Meier; OS: overall survival.<b>Figure S4.</b> Log-cumulative hazard plot for OS. BSC: best supportive care; OS: overall survival.<b>Fig</b><b>ure S5</b><b>.</b> Standard parametric survival model extrapolations for PFS (avelumab + BSC).<b> </b>BSC: best supportive care; KM: Kaplan-Meier; PFS: progression-free survival.<b>Fig</b><b>ure S6</b><b>.</b> Standard parametric survival model extrapolations for PFS (BSC). BSC: best supportive care; KM: Kaplan-Meier; PFS: progression-free survival.<b>Fig</b><b>ure S7</b><b>.</b> Spline-based parametric survival model extrapolations for PFS (avelumab + BSC).<b> </b>BSC: best supportive care; KM: Kaplan-Meier; PFS: progression-free survival.Figure S8. Spline-based parametric survival model extrapolations for PFS (BSC). BSC: best supportive care; KM: Kaplan-Meier; PFS: progression-free survival.Figure S9. Log-cumulative hazard plot for PFS. BSC: best supportive care; PFS: progression-free survival.<b>Fig</b><b>ure S10.</b> Extrapolations for TTD (avelumab + BSC). BSC: best supportive care; KM: Kaplan-Meier; TTD: time to treatment discontinuation.Table S1. Statistical goodness-of-fit scores for OS.Table S2. Statistical goodness-of-fit scores for PFS.<b>Table S3. </b>Model parameters<b>.</b><br>